Biohaven shares pop as FDA accepts resubmission for ataxia drug with adcomm expected
Published . Updated .
Troriluzole, in development for spinocerebellar ataxia, was rejected nearly a year ago when the FDA took issue with the design of Biohaven’s registrational study. The agency has now agreed to review a new application and render a decision in the first quarter of 2027.
Directly affected
- BHVN Biohaven-25.1%
Named in this report.
Indirectly affected
- No related companies are mapped for this report yet.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| BHVN | -2.55% | -3.32% | base | +25.19% | +23.40% | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Biohaven shares pop as FDA accepts resubmission for ataxia drug with adcomm expected BioSpace
Source: BioSpace
This story
| Company | When | Move | Status |
|---|---|---|---|
| BHVN | that day | +25.19% | final price |
| BHVN | the next day | +23.40% | still updating |
| BHVN | three days earlier | -3.32% | final price |
| BHVN | five days earlier | -2.55% | final price |
| GLD | that day | -2.61% | final price |
| GLD | three days earlier | +0.18% | final price |
| GLD | five days earlier | +0.98% | final price |
| QQQ | that day | -2.85% | final price |
| QQQ | three days earlier | -0.96% | final price |
| QQQ | five days earlier | +0.41% | final price |
| SPY | that day | -1.18% | final price |
| SPY | three days earlier | -0.84% | final price |
| SPY | five days earlier | -0.18% | final price |
| TLT | that day | +1.86% | final price |
| TLT | three days earlier | -0.97% | final price |
| TLT | five days earlier | -0.31% | final price |
This story
12 out of 100Price not final
“Biohaven shares pop as FDA accepts resubmission for ataxia drug with adcomm expected” scores 12 out of 100. The score uses 1 sources. The price is not final yet.